F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy
Condition: Central Nervous System Cancer
Sponsor: Fore Biotherapeutics
Full Title
F8294-201b: A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations
Study Treatment
Oral BRAF inhibitor FORE8394 in combination with cobicistat
Eligibility/Info
For the treatment of patients with a BRAF V600E mutant CNS primary malignancy that has recurred or continued to grow after at least 1 prior line of therapy including radiation.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
Need More Information?
Our team is here to help answer your questions and guide you through your options.